Rimonabant and taranabant are two extensively studied cannabinoid-1 receptor (CB1R) inverse agonists. Their effects on in vivo peripheral tissue metabolism are generally well replicated. The central nervous system site of action of taranabant or rimonabant is firmly established based on brain receptor occupancy studies. At the whole-body level, the mechanism of action of CB1R inverse agonists includes a reduction in food intake and an increase in energy expenditure. At the tissue level, fat mass reduction, liver lipid reduction and improved insulin sensitivity have been shown. These effects on tissue metabolism are readily explained by CB1R inverse agonist acting on brain CB1R and indirectly influencing the tissue metabolism through the autonomic nervous system. It has also been hypothesized that rimonabant acts directly on adipocytes, hepatocytes, pancreatic islets or skeletal muscle in addition to acting on brain CB1R, although strong support for the contribution of peripherally located CB1R to in vivo efficacy is still lacking. This review will carefully examine the published literature and provide a perspective on what new tools and studies are required to address the peripheral site of action hypothesis.
Introduction
Cannabinoid-1 receptors (CB1Rs) are predominantly expressed in the central nervous system (CNS) and PNS (peripheral nervous system).
1,2 Based on sensitive detection techniques, such as PCR, CB1R mRNA has also been detected in some peripheral organs or isolated non-neuronal cells, although the detected mRNA in peripheral tissues or organs may represent mRNA from neurons within the peripheral tissues. Most of the literature in the CB1R research field supports the prominent role of brain CB1R in mediating various pharmacological effects of drugs. Some investigators also proposed a hypothesis that includes peripheral nonneuronal CB1R as part of the mechanism of action (MOA) of CB1R inverse agonists. 3, 4 The peripheral MOA hypothesis received renewed interests when it became apparent that a peripherally restricted compound may be devoid of the psychiatric adverse effects exhibited by rimonabant and taranabant. 3 Many reviews have been published summarizing the observed in vivo efficacy of CB1R inverse agonists in animals and humans. [5] [6] [7] [8] However, a critical assessment for the peripheral site of action hypothesis has not been conducted. We will examine the available data to outline a consensus understanding for a MOA with widespread experimental support, and highlight unanswered questions. This review will focus on the physiological MOA of inverse agonists and whether peripheral CB1R plays a significant role in the metabolic effects of inverse agonists. Properly demonstrating the peripheral CB1R contribution should provide a basis to evaluate whether a new generation of CB1R inverse agonists can be used in the treatment of metabolic disorders.
Molecular and cellular MOA
The MOA of a drug can be considered at the molecular, cellular and physiological level. At the molecular level, a drug targeting a receptor can be acting as an agonist, a neutral antagonist or an inverse agonist. 9 This definition is on the basis of data from in vitro assay rather than in vivo assay. Some receptors exhibit constitutive activity, which is defined as receptor signaling activity in the absence of agonist. When a receptor does not exhibit constitutive activity, neutral antagonist and inverse agonist collapse into the same class of ''antagonist''. However, when a receptor does exhibit constitutive activity as in the case of CB1R, neutral antagonist and inverse agonist are distinct pharmacological entities and can be experimentally differentiated under conditions when agonist is not present. 10 In the case of CB1R ligands, all three classes of compounds (agonists, neutral antagonists and inverse agonists) have been discovered. Taranabant and rimonabant have been shown in numerous studies to exhibit inverse agonist properties ( Figure 1 ). [11] [12] [13] [14] [15] [16] [17] In the literature, some authors have continued to use the term antagonist, and some authors have used the term antagonist/inverse agonist to describe rimonabant and taranabant. It should be pointed out here that the term antagonist emphasizes its ability to antagonize the agonist effect, and the term inverse agonist emphasizes its ability to inhibit CB1R activity in the absence of agonist.
As we showed, inverse agonists also competitively antagonize the agonist effect. 11 Hence, qualitative terms such as inverse agonist/antagonist at the CB1R do not explain the difference between these two molecules. They differ in areas of potency, selectivity, off-target activity, pharmacokinetic properties and toxicological profiles. At the cellular level, it has been well documented that CB1R agonists inhibit neurotransmitter release, whereas inverse agonists increase neurotransmitter release. [18] [19] [20] [21] [22] This cellular MOA is also consistent with the molecular distinction between agonist and inverse agonist. Although most comparisons of agonists to inverse agonists are on the basis of recombinant expression systems, ex vivo assays of brain slice electrophysiology have indicated that rimonabant's effect is consistent with an inverse agonist effect under these conditions, in which the likelihood of endocannabinoid release is low.
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Physiological MOA
The physiological effects after CB1R inverse agonist treatment in animals and humans include inhibition of food intake and increase of energy expenditure. 11, [23] [24] [25] Although the molecular basis and cellular basis for the action of inverse agonists have been well documented and the physiological endpoints are well defined, the detailed physiological mechanisms through which modulation of CB1R translate to changes in peripheral tissue metabolism can be difficult to dissect. The following sections will address the physiological MOA related to the site of action for inverse agonists and the physiological pathways involved. When evaluating the MOA of drugs in whole animals, the effects of a drug need to be separated from the site of action of the drug. A drug can act on a brain target and produce peripheral tissue effects mediated through the autonomic nervous system. Alternately, a drug can act on a molecular target within the peripheral organs to produce an effect ( Figure 2 ). Many bodily functions, such as body temperature, metabolism and endocrine functions, are controlled by the brain. Hence, the demonstration of a peripheral tissue effect 
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Peripheral physiological effects vs peripheral site of action for a drug
When assessing the effects of CB1R inverse agonists, it is important to recognize that many groups have reproduced a wide variety of physiological effects in vivo, including reduction of food intake, increase in energy expenditure, reduction of fat mass and reduction of liver lipid content. Food intake reduction and energy expenditure increase are two important components of the MOA of taranabant, 11, 25 and both of these pharmacodynamic effects can lead to reduction of fat mass and liver lipid content. Food intake reduction and energy expenditure increase have also been shown in rodents for rimonabant or AVE1625. [26] [27] [28] Although the in vivo effects of CB1R inverse agonists are well replicated, the site of action for some of these drugs has been debated, specifically regarding whether peripherally located CB1R mediates the in vivo effects. Taranabant clearly acts on brain CB1R as shown by the brain penetration of the compound, the brain CB1R occupancy and the correlation between brain CB1R occupancy and efficacy on weight loss and food intake. 11, 29 Other groups also showed that rimonabant occupies brain CB1R at doses that produce significant physiological effects. 30 There is only one report suggesting that central administration of rimonabant or endocannabinoids through intracerebroventricular (icv) injection did not affect food intake. 31 In contrast, it has been shown in independent studies that direct injection of agonists into brain can stimulate food intake, 32, 33 and icv administration of rimonabant does reduce food intake and body weight. 34 Based on the totality of these reports, it seems to be that the negative result of Gomez et al. 31 may represent a special limitation of the study. One of the reasons for the difficulty of proving the contribution of peripherally located CB1R by conventional in vivo studies is the communication between the CNS and peripheral organs. Autonomic nerve innervation of adipose tissue, liver and pancreas has been well established in the literature. [35] [36] [37] [38] [39] [40] As the brain clearly controls whole body metabolism through the autonomic nervous system, it is generally expected that centrally acting CB1R inverse agonists can lead to various peripheral physiological effects. Showing the direct contribution of peripherally located CB1R will require specifically designed experiments.
Experimental approaches to show a peripheral site of drug action
As low levels of CB1R mRNA can be detected by PCR in adipocytes and liver, it has also been hypothesized that direct actions of rimonabant on adipocytes 4 or hepatocytes 41, 42 may contribute to the observed physiological effects. It is impossible to show by conventional in vivo studies whether the physiological effects of CB1R inverse agonists may include a component of the peripheral site of action, because of the intact communication between the brain and peripheral tissues. To address the question of potential peripheral site of action, three experimental approaches can be used as follows: (a) a pharmacological approach using a non-brain-penetrating compound; (b) a combination of pharmacological approach and genetic or surgical approach in which CNS CB1R can be deleted or the CNS-PNS connection is disrupted; (c) in vitro cell culture studies in which the influence of CNS is absent.
(a) Non-brain-penetrating compounds or other pharmacological approaches In vitro and in vivo behavioral studies using one non-brainpenetrating CB1R antagonist SR140098 have been published, 43 although its structure and its effect on energy balance and metabolism have not been disclosed. A nonbrain-penetrating compound clearly represents an extremely valuable tool in addressing whether inhibiting peripheral CB1R can lead to metabolic efficacy. Toward that end, Pavon 44 hypothesized that a newly discovered molecule, LH-21, might not cross the blood-brain barrier. However, LH-21 has since been shown to be brain penetrant and its weight loss efficacy is not mediated by CB1R, because LH-21 is still effective in CB1R KO mice. 45 More recently, another molecule (URB447) was reported to be non-brain penetrant. 46 Like LH-21, URB447 has a low affinity at CB1R
(IC50 ¼ 313 nM). As URB447 has not been shown to lack efficacy in CB1R KO mice, its mechanism-based efficacy in wild-type (WT) mice needs to be confirmed before this molecule can be used to test the peripheral CB1R hypothesis. Without a non-brain-penetrating compound, one group has attempted to determine whether central administration of rimonabant can produce different effects compared with systemic administration. In the studies by Nogueiras et al., 34 it was reported that differential effects were observed with icv or i.p. administration of rimonabant. Rimonabant at 10 mpk (i.p.) but not 5 ug (icv) led to reduction of triglyceride content in white adipose tissue (WAT) or improved insulin sensitivity. However, these differences are also consistent with other explanations. For example, with i.p. administration of a brain-penetrating compound, the entire brain is exposed to the compound. In contrast, icv administration of a compound does not necessarily produce the same brain exposure to the compound as i.p. administration. It has been well documented that certain small molecules may not reach the entire brain after icv administration, 47, 48 whereas systemic administration of brain-penetrating molecules will expose the whole brain. Different brain substrates can also independently affect food intake and energy expenditure. 49 In the absence of CB1R occupancy measurement or CB1R mechanism of action TM Fong and SB Heymsfield compound diffusion measurement, it would be difficult to ascertain that rimonabant through icv administration would reach the same brain sites as through i.p. administration. These alternative interpretations clearly highlight the need to have a non-brain-penetrating compound to address the specific role of peripherally located non-neuronal CB1R.
(b) Combination of surgical or genetic approach with pharmacological approach In the absence of validated non-brain-penetrating CB1R ligands, one can combine pharmacological approach with a surgical or genetic approach to eliminate or reduce the contribution of CNS CB1R. In a recent study by Verty et al., rimonabant-induced BAT (brown adipose tissue) temperature increase was eliminated when BAT was sympathetically denervated. These data indicate that the rimonabantinduced energy expenditure increase in BAT requires intact communication between the brain and periphery, and BAT temperature increase is likely mediated by rimonabant acting on CNS CB1R. Similar combination of surgical and pharmacological approaches could potentially be applied to the study of metabolism at other peripheral tissues.
A genetic approach may also be useful when combined with a pharmacological approach. For instance, one can produce conditional CNS CB1R KO mice and test brainpenetrating CB1R inverse agonists. In principle, the CNS CB1R KO mice can be designed to retain all CB1R in peripheral tissues, but lack CB1R in the CNS. Such a genetic model can be combined with pharmacological approaches to evaluate the contribution of peripheral CB1R. Although CNS CB1R KO mice have not been reported, CB1R KO in a subpopulation of neurons has been reported. 51 The latter is not appropriate to address the site-of-action question because not all CB1R's are removed from the CNS. More recently, liver-specific CB1R KO mice have been evaluated. 52 This model provides the potential to evaluate CB1R inverse agonist in the presence or in the absence of liver CB1R. With regard to diet-induced obesity (DIO), the liver CB1R KO mice show the same phenotype of DIO as the WT mice, whereas the global KO mice are resistant to DIO. When rimonabant was tested in the WT or liver CB1R KO mice or global KO mice, rimonabant reduces respiratory quotient (RQ) in both the WT and the liver CB1R KO mice but not in the global KO mice. These data indicate that body weight reduction and whole-body fatty acid oxidation increase are not mediated by liver CB1R. When analyzing the high-fat diet-induced steatosis and liver triglyceride content, the liver CB1R KO mice seem to have an intermediate phenotype. Specifically, the liver triglyceride increase and steatosis in the liver KO are still observed, albeit to a lesser extent compared with the WT mice. On the other hand, the global CB1R KO mice are completely resistant to high-fat diet-induced steatosis. Based on these pharmacological and genetic studies, it seems that the effects of rimonabant treatment on body weight and whole-body nutrient utilization are mediated by CNS CB1R. Genetically, deleting liver CB1R leads to a smaller increase in liver triglyceride compared with the WT mice under a high-fat diet condition. When a non-brain-penetrating compound is available, it will be important to test whether pharmacological inhibition of liver CB1R can lead to the improvement of metabolic parameters. 42 (c) In vitro cell culture approach To remove the influence of CNS, in vitro cell culture studies can be conducted to evaluate the effect of CB1R inverse agonists on adipocyte metabolism, hepatocyte metabolism and pancreatic b-cell functions. Although cell culture conditions do not necessarily represent in vivo cellular conditions and positive outcomes from such in vitro studies do not necessarily translate into in vivo beneficial effects, these studies could provide a theoretical basis for a direct action of CB1R inverse agonists on non-neuronal cells.
Adipocytes
Of all the peripheral organs (besides the GI (gastrointestinal) tract), adipose tissue is the tissue where CB1R mRNA has been consistently detected by PCR, which is a highly sensitive method of detection. Although CB1R mRNA (or at least the fragment as detected by PCR) is clearly detected, whether the CB1R protein is functional in adipocytes is controversial.
Using primary adipocytes from mice, it was reported that a non-selective agonist WIN55212 can increase LPL (lipoprotein lipase) activity at 1 uM 53 ( Figure 3 ). However, rimonabant alone at 1 uM did not reduce LPL activity, and WIN55212 alone at 100 nM did not have any effect on LPL activity. As WIN activates CB1R with an EC50 of 20 nM in cell-based cAMP assay, 54 it is not clear whether the LPL effect of WIN at 1 uM is mediated by CB1R. Furthermore, WIN has not been tested using adipocytes isolated from CB1R KO 
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CB1R mechanism of action TM Fong and SB Heymsfield mice. For this WIN effect to be translated to meaningful endocannabinoid effect in vivo, the endocannabinoid levels need to be much higher than their CB1R EC50 values. Thus far, such a high level of endocannabinoids has not been reported. For example, plasma anandamide levels were reported to be B50-fold lower than its EC50 value at CB1R. 55 Whether the local anandamide level within the adipose tissue is higher than circulating level is not yet known.
Using a preadipocyte 3T3 cell line, adipocytes can be differentiated from preadipocytes in the presence of insulin. 4 Under such conditions, rimonabant was reported to increase adiponectin mRNA levels at 50 or 100 nM but not at 25 nM or 200 nM (Figure 4) . The reason for such a narrow concentration-dependence for the rimonabant effect is not clear. Furthermore, it is not clear whether adiponectin protein secretion is affected by rimonabant. In humans, the plasma Cmax of rimonabant at 20 mg after 21 days of dosing is B380 nM. 56 The direct effects of rimonabant on adipocytes has not been widely replicated by other groups. 57, 58 Using a similar cell culture approach, Hamilton et al. 58 reported that cAMP level and lipolysis were not affected by rimonabant, whereas a b-agonist did increase cAMP or lipolysis. Using either a cell culture approach or in vivo studies, Hamilton et al. 58 reported that adiponectin mRNA is not affected by rimonabant, whereas rosiglitazone did increase adiponectin mRNA. Similar studies conducted by us did not detect significant changes in lipolysis or lipogenesis induced by CB1R agonists or inverse agonists in cell culture assays (Fong et al, unpublished) . In another study using human primary adipocytes, adiponectin mRNA was not affected by either rimonabant or WIN55212. 59 In addition, Lofgren et al.
57
reported that human CB1R mRNA levels in adipose biopsy samples were not related to fat-cell function or adiponectin level. In summary, some of the positive findings in adipocyte studies are not easily reconciled with the known in vitro pharmacological potency of WIN55212 or rimonabant, and these adipocyte results have not been replicated by other groups. It remains a challenge to show a consistent direct effect of CB1R inverse agonists on adipocyte functional readouts in vitro.
Hepatocytes
Osei-Hyiaman et al. 41 have reported the presence of CB1R mRNA in liver, although the level is clearly very low. Using primary hepatocytes from mice, it was found that CB1R agonist HU210 (100 nM) can increase fatty acid synthesis, whereas rimonabant (10 nM) can decrease fatty acid synthesis ( Figure 5 ). The HU210-induced increase was shown to be absent in hepatocytes from CB1R KO mice. 41 Whether the rimonabant-induced fatty acid synthesis reduction is mediated by CB1R has not been tested, presumably because of the fact that fatty acid synthesis in the hepatocytes of the KO mice is already very low. The published data of Osei-Hyiaman et al. 41 are comprehensive, encompassing both genetic model and pharmacological studies. As discussed in section (b), the role of liver CB1R awaits further pharmacological validation using a non-brain-penetrating inverse agonist.
Pancreatic islets
Matias et al. 60 reported that a CB1R agonist stimulates glucose-dependent insulin secretion (GDIS) in rat insulinoma RIN-m5F cells. These results would predict that inverse agonists should inhibit glucose-dependent insulin release. Given that rimonabant has been shown to improve glycemic control in diabetic patients, the prediction of Matias et al.
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is counter-intuitive as many anti-diabetic agents such as GLP-1 are known to stimulate GDIS. Using isolated mouse islets, Juan-Pico 61 reported that CB1R agonists inhibit GDIS. Nakata et al. 62 also reported that CB1R agonists inhibit GDIS in mouse islets. Both 
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Juan-Pico 61 and Nakata 62 did not evaluate CB1R inverse agonists. In a 2007 American Diabetes Association (ADA) presentation, Getty-Kaushik et al. 63 reported that rimonabant at high concentration (1 uM) can inhibit GDIS in islets from lean Zucker rats. The conclusions from these four published studies vary greatly (Table 1) , hence the direct effect of CB1R inverse agonists on islets seems difficult to reconcile.
Skeletal muscle
Liu et al. 27 conducted in vivo experiments with rimonabant and showed that the treatment of ob/ob mice with rimonabant for 7 days led to increased glucose uptake in muscle. This study is often misquoted as evidence that rimonabant acts on skeletal muscle directly. However, this is an in vivo study and does not address the site of drug action. A recent article reported that incubating isolated human myotubes with 5 uM of AM251 led to a small change in the mRNA levels of several enzymes, such as AMPK or PDK4. 64 As the requirement of high concentration is in contrast to the known in vitro binding affinity and intrinsic inverse agonist potency of AM251, it is unclear whether these effects are indeed mediated by CB1R. Further studies will be needed to address these unanswered questions.
Do CB1R agents produce weight loss-independent effects?
Currently, there are no published experimental data to support the hypothesis of weight loss-independent effects. It has been reported that AM251 lacks acute effects on glucose homeostasis in DIO mice when AM251 acutely affects body weight in DIO mice. 65 Whether long-term treatment with a low dose of a CB1R inverse agonist can produce glycemic effect without body weight effect has not been reported. It is also possible that a significant reduction of regional fat mass may not be reflected in a body weight change, but the reduction of regional fat mass may be sufficient to improve insulin sensitivity. If this is true, an apparent weight loss-independent effect can actually be a regional fat mass reduction-dependent effect. Further studies are needed to clarify the relationship among abdominal fat mass, liver lipid content, body weight and other metabolic parameters.
In clinical studies, statistical modeling has suggested that a portion of the lipid profile improvement and glucose profile improvement is not explained by a weight loss effect. However, post-hoc statistical modeling is not generally accepted as proof of a weight loss-independent effect. 66 Specifically designed studies will be needed to address this question.
How does the CB1R affect feeding behaviorFrole of CB1R on appetite, satiety/satiation and craving
The central control of feeding behavior can be manifested in several different ways. Appetite refers to the tendency to seek food and consume food. 67, 68 A drug can act on distinct components of the appetite control mechanism, including psychological events of hunger perception or craving, or temporally distinct components of pre-meal hunger, satiation during a meal (which causes meal termination) or postmeal state of satiety. Limited experimental data exist to elucidate the details of how CB1R inverse agonists affect these different components. In one clinical trial of rimonabant, it was shown that rimonabant reduces food craving and hunger at the start of a meal with no change in the sensation of fullness after meals, implying an improved control of the pre-meal motivation to eat. In addition, the reduction in food intake is independent of food type and pleasantness, and rimonabant does not affect the pleasantness of food. 69 In another clinical trial of taranabant, Addy et al. 25 showed that taranabant reduces the intake of all three major macronutrients (carbohydrate, fat and protein). These data show that CB1R inverse agonists inhibit pre-meal motivation to eat, craving and hunger and enhance satiation (that is, meal termination). Based on the co-localization of CCK1R and CB1R in vagal nerves and the observation that CCK agonist or antagonist can affect the expression level of CB1R in vagal afferent neurons, 70 it has been hypothesized that CB1R inverse agonist may affect satiety. 71 However, the co-localization per se does not necessarily support a satiety effect. To further validate this hypothesis, it is necessary to show that CB1R inverse agonists affect vagal nerve activity in a similar manner as CCK or CB1R inverse agonists affect satiety in behavioral studies. In rodent lever-pressing studies in which food (either palatable or non-palatable) was used as reinforcer, rimonabant was found to suppress the lever-press response rate, consistent with the interpretation that CB1R inverse agonists reduce the rewarding efficiency of food with no selectivity on palatability. 72, 73 In addition, food intake studies showed that rimonabant inhibited the intake of both regular chow or palatable food. 24, 74, 75 Tetrahydrocannabinol (THC) has also been shown to stimulate the intake of either chow or highfat sweetened diet. 76 These data generally support a model in which CB1R inverse agonists reduce the intake of all macronutrients with no selectivity related to palatability. 
Current understanding and conclusions
The CNS site of action of CB1R inverse agonists is firmly established, and the effects on in vivo metabolism of peripheral organs (such as, reduction of fat mass, increased energy expenditure and reduction of liver lipids) are generally well replicated by multiple groups. Whether inverse agonists act on adipose, liver, pancreas or skeletal muscle directly is not yet confirmed. Key unanswered questions have been raised here. In general, current data are most consistent with the notion that brain CB1R plays a key role in inverse agonist-induced changes in body weight, food intake and energy expenditure. At the whole-body level, the MOA of CB1R inverse agonists include reduction of appetite and increase in energy expenditure, which ultimately lead to reduced weight (Figure 6) . At the tissue level, fat mass reduction, liver lipid reduction and improved insulin sensitivity have been shown. The effects on tissue metabolism are readily explained by CB1R inverse agonists acting on brain CB1R and indirectly influencing tissue metabolism through the autonomic nervous system. Nonetheless, the contribution of peripheral non-neuronal CB1R remains a possibility, especially in the case of liver steatosis. New tools such as nonbrain-penetrating compounds or brain-specific CB1R KO mice will be needed to define the specific role of peripheral CB1R in mediating the pharmacological effects of inverse agonists. CB1R mechanism of action TM Fong and SB Heymsfield
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